Osteoarthritis After a Heart Attack: Choosing an NSAID in Light of the PRECISION Trial
A patient with a prior MI and a prior GI bleed needs an NSAID for osteoarthritis pain. The old instinct is to avoid celecoxib and reach for naproxen — the PRECISION trial found the opposite may serve her better.
Renata S., 66, has walked a school crossing route five mornings a week for the better part of a decade, work she describes as the one part of retirement she never actually retired from, and the one thing she's least willing to give up even as her hands and knees have made the job harder than it used to be. Osteoarthritis in both has been building for four years, enough now that gripping the crossing-guard stop sign through a cold morning has become genuinely painful, and acetaminophen with topical diclofenac isn't touching it the way it once did. Her history carries two real, independent reasons most clinicians would hesitate before adding an oral NSAID: an anterior MI three years ago, treated and stable since on aspirin, a statin, and a beta-blocker, and a peptic ulcer with a documented GI bleed eight years before that, its underlying cause treated and not recurred since. Neither event, she points out, has anything to do with the other — they just both happened to her.
The reflexive move for a patient with cardiovascular disease is to avoid celecoxib specifically — a holdover from rofecoxib's withdrawal two decades ago — and default to naproxen as 'the safe NSAID.' The 2016 PRECISION trial tested that assumption directly in more than 24,000 patients with arthritis at elevated cardiovascular risk, randomized to celecoxib, naproxen, or ibuprofen, all with background PPI therapy. Celecoxib was non-inferior on the primary cardiovascular endpoint — 2.3% versus 2.5% for naproxen and 2.7% for ibuprofen — and had meaningfully fewer gastrointestinal events than either comparator. Renata carries exactly the two risk factors that trial measured, in combination, and the drug the older instinct steers away from is the one its own numbers favor for her specific pairing of risks.
Choosing an NSAID with a cardiac history and a GI history both on the chart
My instinct with any patient carrying a documented MI is to stay away from COX-2-selective agents. That caution predates PRECISION and I'm not going to pretend it doesn't color how I read a request like this — celecoxib inherited rofecoxib's reputation even though it's a different molecule, and old habits in cardiology don't move quickly.
And before PRECISION gets put on the table as though it closes this — it enrolled her population, but it did not compare equivalent doses. Osteoarthritis patients in that trial were held at celecoxib 100mg twice daily; the mean daily doses across the three arms came out at roughly 209mg of celecoxib against 852mg of naproxen and 2045mg of ibuprofen. Non-inferiority at a modest dose of one drug against fuller doses of two others is a narrower finding than "celecoxib is as safe."
So I'd default to naproxen with a PPI as the more conservative starting point for a patient with her cardiac history, specifically because it's the NSAID with the longest track record of not raising alarm in coronary populations.
I understand the instinct, but PRECISION exists specifically to test it, and it tested it in patients who look like Renata — arthritis, elevated cardiovascular risk, needing daily NSAID therapy. Celecoxib wasn't just non-inferior on the composite cardiovascular endpoint; naproxen's own reputation as 'the safe one' didn't hold up either, since all three arms landed in the same narrow 2.3 to 2.7 percent range.
The dosing point is a real limit and I won't wave it away — but notice what it does to your own recommendation rather than to mine. If the celecoxib arm was underdosed relative to the comparators, then 100mg twice daily is precisely the exposure that was actually tested and found non-inferior, and 100mg twice daily is exactly what I'm proposing for her. The criticism bites against extrapolating to 200mg twice daily. It doesn't bite against the dose on the prescription.
And where celecoxib actually separated from the other two was gastrointestinal events — 1.1% with celecoxib against 1.5% with naproxen and 1.6% with ibuprofen. Renata has a real, documented GI bleed on her record. Choosing naproxen over celecoxib for her specifically trades a cardiovascular risk the trial found equivalent for a gastrointestinal risk the same trial found celecoxib handles better.
Both of you are right about your own piece of this, and I don't think the disagreement is really about which drug — it's about how much standing NSAID exposure a woman with two independent prior events actually needs. PRECISION's own numbers say no arm was free of cardiovascular events; two to three percent isn't nothing at that scale.
Start celecoxib, low dose, with a PPI, given her GI history specifically — that part of the rheumatologist's argument is the more directly relevant one for Renata. But treat it as the smallest effective and shortest reasonable course rather than an indefinite daily prescription, and lean harder on topical therapy and acetaminophen in between flares so we're not defaulting to standing oral NSAID coverage just because we've settled which one to use.
Agreed: celecoxib 100mg twice daily with omeprazole, prescribed as the smallest effective, time-limited course rather than an open-ended standing prescription, with topical diclofenac and acetaminophen continued for her hands and for breakthrough days.
Not fully agreed: how short 'shortest effective course' should actually be in practice. The cardiologist wanted a hard reassessment at four weeks regardless of how she's doing; the rheumatologist argued a rigid deadline risks undertreating her if she's genuinely doing well, and preferred reassessing by symptom trajectory rather than the calendar. Both agreed to revisit her renal function and blood pressure at that first follow-up regardless of which reassessment logic wins out.